Evidence map›Paper›PMID 38155272›Full record

ArticleBreast cancer research and treatment2024

Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.

Faina Nakhlis, Samuel M Niman, Naoto T Ueno, Elizabeth Troll, Sean Ryan, Eren Yeh, Laura Warren, Jennifer Bellon, Beth Harrison, Toshiaki Iwase and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Faina NakhlisDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Ave, Yawkey Suite 1220, Boston, MA, 02215, USA. fnakhlis1@bwh.harvard.edu.ORCID http://orcid.org/0000-0003-4752-0161
Samuel M NimanInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Naoto T UenoDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth TrollInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Sean RyanInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Eren YehInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Laura WarrenInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Jennifer BellonInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Beth HarrisonInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Toshiaki IwaseDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H T Carisa Le-PetrossDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sadia SaleemDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mediget TeshomeDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gary J WhitmanDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wendy A WoodwardDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Beth OvermoyerInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Sara M TolaneyInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Meredith ReganInflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Filipa Lynce *Inflammatory Breast Cancer Program, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Rachel M Layman *Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USBrigham and Women's Hospital · USHarvard University · USDana-Farber Brigham Cancer Center · USDana-Farber Cancer Institute · USUniversity of Hawaiʻi at Mānoa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMany stage III inflammatory breast cancer (IBC) patients experience a sufficient response to first-line (1L) neoadjuvant chemotherapy (NAC) to allow surgery, while some require additional NAC. We evaluated the pathologic complete response (pCR), breast cancer-free survival (BCFS) and overall survival (OS) among patients requiring 1 vs. 2-3 lines (L) of NAC prior to surgery.

methodsStage III IBC patients from 2 institutions who received 1L or 2-3L of NAC prior to surgery were identified. Hormone receptor and HER2 status, grade, and pCR were evaluated. BCFS and OS were evaluated by the Kaplan-Meier method. Multivariable Cox models were utilized to estimate the hazard ratio (HR).

results808 eligible patients (1997-2020) were identified (median age 51 years, median follow-up 69 months). 733 (91%) had 1L and 75 (9%) had 2-3L of NAC. Grade III, triple-negative and HER2-positive disease were more prevalent in 2-3L patients. 178 (24%) 1L and 14 (19%) 2-3L patients had pCR. 376 1L patients and 41 2-3L patients had recurrences. The 5-year BCFS was worse for the 2-3L group (33 vs. 46%, HR = 1.37; 95% CI 0.99-1.91). However, in 192 patients with a pCR, BCFS was similar (76 vs. 83% in 1L vs. 2-3L, respectively). There were 308 deaths (276 among 1L and 32 among 2-3L patients). The 5-year OS in 1L vs. 2-3L was 60 vs. 53% (HR = 1.32, 95% CI 0.91-1.93).

conclusionsAmong stage III IBC patients, pCR rates were similar, irrespective of the NAC lines number, and BCFS and OS were comparable with pCR after 1L and 2-3L.

Indexed as

Breast NeoplasmsInflammatory Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingErb-b2 Receptor Tyrosine KinasesInflammatory breast cancerNeoadjuvant chemotherapyPathologic complete responseResectability

Identifiers

PMID38155272
OpenAlexW4390336523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.